Neprilysin

• 

  Subject Areas on Research

  • An unusual nodal marginal zone lymphoma with bright CD10 expression: a potential diagnostic pitfall. 
  • Analysis of responses to big endothelin in the hindquarters vascular bed of the cat. 
  • Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. 
  • Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact. 
  • Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. 
  • Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial. 
  • Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. 
  • Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction. 
  • Association of Changes in Heart Failure Treatment With Patients' Health Status: Real-World Evidence From CHAMP-HF. 
  • BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. 
  • Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. 
  • Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. 
  • Bombesin-like peptides and receptors in normal fetal baboon lung: roles in lung growth and maturation. 
  • CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. 
  • CD10 expression in trichoepithelioma and basal cell carcinoma. 
  • CD10 marks non-canonical PPARγ-independent adipocyte maturation and browning potential of adipose-derived stem cells. 
  • CD10/NEP in non-small cell lung carcinomas. Relationship to cellular proliferation. 
  • CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. 
  • CD10/neutral endopeptidase 24.11 in developing human fetal lung. Patterns of expression and modulation of peptide-mediated proliferation. 
  • CD10/neutral endopeptidase 24.11 regulates fetal lung growth and maturation in utero by potentiating endogenous bombesin-like peptides. 
  • CD10/neutral endopeptidase inhibition augments pulmonary neuroendocrine cell hyperplasia in hamsters treated with diethylnitrosamine and hyperoxia. 
  • Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial. 
  • Characterization of renal neoplasms with monoclonal antibodies to leukocyte differentiation antigens. 
  • Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction. 
  • Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. 
  • Clinical and biologic features predict a poor prognosis in acute lymphoid leukemias in infants: a Pediatric Oncology Group Study. 
  • Clinicopathologic findings in high-grade B-cell lymphomas with typical Burkitt morphologic features but lacking the MYC translocation. 
  • Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. 
  • Comparative Effect of Angiotensin Receptor Neprilysin Inhibition on B-type Natriuretic Peptide Levels Measured by Three Different Assays: The PROVE-HF Study. 
  • Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. 
  • Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). 
  • Detection of minimal residual T cell acute lymphoblastic leukemia by flow cytometry. 
  • Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF). 
  • Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure. 
  • Evaluation of Maternal, Embryo, and Placental Effects in CD-1 Mice following Gestational Exposure to Perfluorooctanoic Acid (PFOA) or Hexafluoropropylene Oxide Dimer Acid (HFPO-DA or GenX). 
  • Expression of protooncogene c-myb in normal human hematopoietic cells. 
  • Hyaline globules in neuroendocrine and solid-pseudopapillary neoplasms of the pancreas: a clue to the diagnosis. 
  • Immunologic and clinicopathologic features of common acute lymphoblastic leukemia antigen-positive childhood T-cell leukemia. A Pediatric Oncology Group Study. 
  • Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. 
  • Measurement of the growth parameters of precursor B-acute lymphoblastic leukaemic cells in co-culture with bone marrow stromal cells; detection of two cd10 positive populations with different proliferative capacities and survival. 
  • Mechanisms and Models in Heart Failure: A Translational Approach. 
  • Medication Trajectory and Treatment Patterns in Medicare Patients With Heart Failure and Reduced Ejection Fraction. 
  • PARAGON-HF Clinical Trial Eligibility in a Population of Patients Hospitalized With Heart Failure. 
  • Patient Perceptions and Familiarity With Medical Therapy for Heart Failure. 
  • Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States. 
  • Pediatric oncology group utilization of immunologic markers in the designation of acute lymphocytic leukemia subgroups: influence on treatment response. 
  • Pediatric primary bone lymphoma-diffuse large B-cell lymphoma: morphologic and immunohistochemical characteristics of 10 cases. 
  • Pharmacologic Therapy for Heart Failure with Preserved Ejection Fraction. 
  • Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. 
  • Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure. 
  • Relationship Between Hospital Characteristics and Early Adoption of Angiotensin-Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure. 
  • Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction. 
  • Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan. 
  • Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial. 
  • Soluble recombinant neutral endopeptidase (CD10) as a potential antiinflammatory agent. 
  • Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. 
  • The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial. 
  • The human fetal lymphocyte lineage: identification by CD27 and LIN28B expression in B cell progenitors. 
  • The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions. 
  • Variation by race in presenting clinical and biologic features of childhood acute lymphoblastic leukaemia: implications for treatment outcome. 
  • Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities. 
• 

  Keywords of People

  • Sunday, Mary Elizabeth Anne, Professor of Pathology, Cell Biology